In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.

BACKGROUND Mantle cell lymphoma (MCL) has the worst prognosis of all B-cell lymphomas and has poor response to conventional therapy. It is characterized by the presence of a chromosomal translocation t(11:14) (q13;q32) which results in deregulated cyclin D1 expression. Since defects in cell cycle regulation and apoptosis are primary events in MCL, small-molecule inhibitors of cdks-cyclins may play an important role in the therapy of this disorder. CYC202 (Seliciclib, R-roscovitine; Cyclacel Ltd., Dundee, UK) is a purine analogue and a selective inhibitor of the cdk2-cyclin E as well as cdk7-cyclin H and cdk9-cyclin T. MATERIALS AND METHODS The activity of CYC202 was tested in four human MCL cell lines: REC, Granta-519, JeKo-1 and NCEB-1. The effect of CYC202 on the cell cycle and on apoptosis-, cell-cycle- and transcription-regulation-related proteins was assessed. RESULTS The IC50 was 25 microM for REC, Granta-519 and JeKo-1 cells and 50 microM for NCEB-1 cells. CYC202 caused an accumulation of cells in the G2-M phase of the cell cycle and apoptosis. CYC202 caused down-regulation of cyclin D1 and Mcl-1 protein levels, possibly because of the inhibition of transcription elongation. CONCLUSIONS Our data suggest that CYC202 is an active agent in MCL. The concomitant decrease of the phosphorylated and total forms of RNA polymerase II suggests that this could be the main mechanism mediating the biological effects of CYC202 in MCL cells. The drug might represent a new therapeutic agent in this lymphoma subtype.

[1]  F. Cabanillas,et al.  Mantle-cell lymphoma. , 2001, The Lancet. Oncology.

[2]  James Olen Armitage,et al.  A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. , 1997, Blood.

[3]  F. Pisani,et al.  Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26. , 1997, Biochemistry.

[4]  S. Grant,et al.  Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-κB-dependent process , 2003, Oncogene.

[5]  L Meijer,et al.  Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. , 1997, European journal of biochemistry.

[6]  J. Bartek,et al.  Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin’s lymphomas. Functional studies in a cell line (Granta 519) , 1997, Leukemia.

[7]  E. Epner,et al.  Cyclin D1 activation in B-cell malignancy: association with changes in histone acetylation, DNA methylation, and RNA polymerase II binding to both promoter and distal sequences. , 2004, Blood.

[8]  Paul Workman,et al.  The Cyclin-dependent Kinase Inhibitor CYC202 (R-Roscovitine) Inhibits Retinoblastoma Protein Phosphorylation, Causes Loss of Cyclin D1, and Activates the Mitogen-activated Protein Kinase Pathway , 2004, Cancer Research.

[9]  M. Ljungman,et al.  The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382. , 2001, Molecular pharmacology.

[10]  I. Gojo,et al.  The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  Yihong Ma,et al.  Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1. , 2003, Molecular cancer therapeutics.

[12]  A. Lowell,et al.  Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity. , 2003, Cancer research.

[13]  D. Conrad,et al.  The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. , 2003, Cancer research.

[14]  R. Jove,et al.  Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. , 2003, Cancer research.

[15]  E. Sausville,et al.  Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. , 1999, Cancer research.

[16]  H. Döhner,et al.  Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes. , 2002, Blood.

[17]  T. Yoshino,et al.  Establishment and characterization of a mantle cell lymphoma cell line , 1998, British journal of haematology.

[18]  F. Cavalli,et al.  Mantle cell lymphoma: new treatments targeted to the biology. , 2002, Clinical lymphoma.

[19]  P. Fischer,et al.  CDK inhibitors in clinical development for the treatment of cancer , 2003, Expert opinion on investigational drugs.

[20]  D. Lane,et al.  Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. , 2005, Cancer research.

[21]  C. Peschel,et al.  Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells , 2004, Leukemia.

[22]  R. Müller,et al.  Bcl-2 Independence of Flavopiridol-induced Apoptosis , 2000, The Journal of Biological Chemistry.

[23]  Andreas Rosenwald,et al.  Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol , 2001, Genome Biology.

[24]  T. McDonnell,et al.  Expression of Mcl‐1 in mantle cell lymphoma is associated with high‐grade morphology, a high proliferative state, and p53 overexpression , 2003, The Journal of pathology.

[25]  Eun Hee Kim,et al.  Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP , 2004, Oncogene.

[26]  B. Klein,et al.  Expanded range of 11q13 breakpoints with differing patterns of cyclin D1 expression in B‐cell malignancies , 1993, Genes, chromosomes & cancer.

[27]  Nikolai Zhelev,et al.  In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine) , 2002, International journal of cancer.

[28]  E. Zucca,et al.  Molecular basis of mantle cell lymphoma , 2004, British journal of haematology.

[29]  E. Monaco,et al.  Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons. , 2004, Biochemical pharmacology.

[30]  R. Jove,et al.  Roscovitine inhibits STAT5 activity and induces apoptosis in the human leukemia virus type 1-transformed cell line MT-2. , 2003, Cancer research.

[31]  C. Peschel,et al.  Expression of cyclin E in resting and activated B‐chronic lymphocytic leukaemia cells: cyclin E/cdk2 as a potential therapeutic target , 2004, British journal of haematology.